Self-screen and Novosanis have obtained a Eurostar grant named CASUS, which is part of the Horizon 2020 Framework Programme. The CASUS project is meant to develop a complete cervical cancer screening solution based on first-void urine self-sampling. The development is done in cooperation with two academic partners, University of Antwerp and Amsterdam UMC (Vrije Universiteit Amsterdam). The method will include the Colli Pee urine collection device from Novosanis and HPV and methylation CE-IVD tests from Self-screen.